0
Obstructive Lung Diseases |

Prognostication in Patients With Chronic Obstructive Pulmonary Disease Using the BOS Index

Hiang Ping Chan; Amartya Mukhopadhyay; Pauline Chong; Sally Chin; Xue Yun Wong; Venetia Ong; Yiong Huak Chan; Tow Keang Lim; Jason Phua
Author and Funding Information

National University Health System, Singapore, Singapore


Chest. 2015;148(4_MeetingAbstracts):683A. doi:10.1378/chest.2225059
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Poster Discussion

SESSION TYPE: Original Investigation Poster Discussion

PRESENTED ON: Sunday, October 25, 2015 at 01:30 PM - 03:00 PM

PURPOSE: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality worldwide. Many multidimensional tools such as the GOLD 2011 classification, St George’s Respiratory Questionnaire (SGRQ), and the Body mass index (BMI), Obstruction, Dyspnoea, Exercise (BODE) index have been assessed for their prognostic utility in COPD patients. We aim to evaluate the prognostic utility of the BMI, Obstruction and SGRQ (BOS) index. The BOS index is similar to the BODE index but without the 6-minute walk component and with SGRQ replacing the mMRC scores.

METHODS: This is a prospective study involving 1072 patients who were followed between March 2008 and March 2013. They were classified into BOS quartiles according to their scores: Group 1: BOS 0-2; Group 2: BOS 3-4; Group 3: BOS 5; Group 4: BOS 6-7. Outcomes measures were exacerbations and mortality. Multivariable time-to-event analyses (adjusting for age, gender and race) and receiver operator characteristics (ROC) curve were used.

RESULTS: Of the 1072 patients, 285 were in Group 1, 404 in Group 2, 186 in Group 3 and 197 in Group 4. Patients in Group 4 had earlier exacerbations compared to those in Group 1 (HR 0.48, 95% CI 0.36-0.65, p<0.001) and 2 (HR 0.65, 95% CI 0.50-0.84, p=0.001) but not Group 3 (HR 1.03, 95% CI 0.77-1.37, p=0.855). Group 4 also had shorter time to death compared to Group 1 (HR 0.26, 95% CI 0.16-0.42, p<0.001) and 2 (HR 0.54, 95% CI 0.39-0.77, p<0.001) but not Group 3 (HR 0.71, 95% CI 0.64-1.34, p=0.709). Areas under ROC curves (AUC) were 0.62±0.02 and 0.71±0.02 for exacerbation and mortality respectively. These were identical to AUCs obtained when patients were classified according to GOLD 2011.

CONCLUSIONS: BOS index predicts exacerbation and mortality moderately well. It has similar prognostic utility as the GOLD 2011 classification.

CLINICAL IMPLICATIONS: BOS index can be used for prognostication. Patients in Group 3 and 4 will have worse outcomes compared to their counterparts in the less severe groups.

DISCLOSURE: The following authors have nothing to disclose: Hiang Ping Chan, Amartya Mukhopadhyay, Pauline Chong, Sally Chin, Xue Yun Wong, Venetia Ong, Yiong Huak Chan, Tow Keang Lim, Jason Phua

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543